DKK437.20
5.90% today
Copenhagen, Apr 04, 02:39 pm CET
ISIN
DK0060055861
Symbol
CHEMM
Sector

ChemoMetec Target price 2025 - Analyst rating & recommendation

ChemoMetec Classifications & Recommendation:

Buy
67%
Hold
33%

ChemoMetec Price Target

Target Price DKK652.50
Price DKK464.60
Potential
Number of Estimates 2
2 Analysts have issued a price target ChemoMetec 2026 . The average ChemoMetec target price is DKK652.50. This is higher than the current stock price. The highest price target is
DKK675.00 45.29%
register free of charge
, the lowest is
DKK630.00 35.60%
register free of charge
.
A rating was issued by 3 analysts: 2 Analysts recommend ChemoMetec to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ChemoMetec stock has an average upside potential 2026 of . Most analysts recommend the ChemoMetec stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Jun '24 2025
Estimates
Revenue Million DKK 407.35 508.20
7.90% 24.76%
EBITDA Margin 43.76% 52.68%
20.17% 20.38%
Net Margin 33.45% 38.83%
17.22% 16.10%

3 Analysts have issued a sales forecast ChemoMetec 2025 . The average ChemoMetec sales estimate is

DKK508m
Unlock
. This is
10.59% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK512m 11.42%
Unlock
, the lowest is
DKK501m 9.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK407m 7.90%
2025
DKK508m 24.76%
Unlock
2026
DKK591m 16.31%
Unlock
2027
DKK680m 15.10%
Unlock

3 Analysts have issued an ChemoMetec EBITDA forecast 2025. The average ChemoMetec EBITDA estimate is

DKK268m
Unlock
. This is
19.46% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK273m 21.87%
Unlock
, the lowest is
DKK260m 16.03%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 DKK178m 26.47%
2025
DKK268m 50.17%
Unlock
2026
DKK309m 15.39%
Unlock
2027
DKK361m 16.77%
Unlock

EBITDA Margin

2024 43.76% 20.17%
2025
52.68% 20.38%
Unlock
2026
52.26% 0.80%
Unlock
2027
53.01% 1.44%
Unlock

3 ChemoMetec Analysts have issued a net profit forecast 2025. The average ChemoMetec net profit estimate is

DKK197m
Unlock
. This is
16.68% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK203m 19.80%
Unlock
, the lowest is
DKK191m 13.17%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK136m 23.76%
2025
DKK197m 44.85%
Unlock
2026
DKK227m 14.82%
Unlock
2027
DKK264m 16.39%
Unlock

Net Margin

2024 33.45% 17.22%
2025
38.83% 16.10%
Unlock
2026
38.33% 1.29%
Unlock
2027
38.76% 1.12%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Jun '24 2025
Estimates
Earnings Per Share DKK 7.83 11.34
23.76% 44.83%
P/E 40.96
EV/Sales 15.40

3 Analysts have issued a ChemoMetec forecast for earnings per share. The average ChemoMetec EPS is

DKK11.34
Unlock
. This is
16.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK11.64 19.75%
Unlock
, the lowest is
DKK11.00 13.17%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK7.83 23.76%
2025
DKK11.34 44.83%
Unlock
2026
DKK13.02 14.81%
Unlock
2027
DKK15.16 16.44%
Unlock

P/E ratio

Current 47.82 6.77%
2025
40.96 14.35%
Unlock
2026
35.68 12.89%
Unlock
2027
30.65 14.10%
Unlock

Based on analysts' sales estimates for 2025, the ChemoMetec stock is valued at an EV/Sales of

15.40
Unlock
and an P/S ratio of
15.91
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.03 4.49%
2025
15.40 9.55%
Unlock
2026
13.24 14.02%
Unlock
2027
11.51 13.12%
Unlock

P/S ratio

Current 17.59 4.35%
2025
15.91 9.57%
Unlock
2026
13.68 14.02%
Unlock
2027
11.88 13.12%
Unlock

Current ChemoMetec Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
DNB MARKETS
Locked
Locked
Locked Nov 10 2024
Analyst Rating Date
Locked
DNB MARKETS:
Locked
Locked
Nov 10 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today